RxDoctor Payments Data

Gregory Johnsen, MD

Interventional Cardiology · Tulsa, OKNPI 1710957105

Payments from drug & device makers

$1,267in general payments, 2019–2025

Across 35 payments — averaging $36.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$310
  • Abbott$282
  • Boston Scientific$247
  • Novartis$130
  • Esperion Therapeutics, Inc.$125
  • Amgen$53
  • plus $120 from 5 others

What the payments were for

  • Food & beverage$1,25399%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,267 in reported general payments places this provider in the 10th percentile of 110 interventional cardiology providers in Oklahoma.

See all interventional cardiology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$116,853
Medicare patients
702
Services billed
1,270

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban291$262,184
Repatha SureclickEvolocumab57$72,768
EntrestoSacubitril/Valsartan71$62,178
XareltoRivaroxaban55$51,581
BrilintaTicagrelor37$18,255
FarxigaDapagliflozin Propanediol22$12,340
Ezetimibe364$7,229
Rosuvastatin Calcium412$6,958
Metoprolol Succinate372$4,500
Atorvastatin Calcium432$4,363
Amlodipine Besylate306$2,410
Ranolazine ErRanolazine23$2,142
Losartan Potassium196$2,055
ClopidogrelClopidogrel Bisulfate154$1,811
Carvedilol198$1,689

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$262,184291 claims
NovartisEntresto$130$62,17871 claims
AstraZenecaBrilinta, Farxiga$14$30,59559 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 110 interventional cardiology providers in Oklahoma.

Other interventional cardiology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →